Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 204.81M P/E - EPS this Y - Ern Qtrly Grth -
Income -55.99M Forward P/E - EPS next Y - 50D Avg Chg 2.00%
Sales 26.08M PEG - EPS past 5Y - 200D Avg Chg -4.00%
Dividend N/A Price/Book 0.78 EPS next 5Y - 52W High Chg -49.00%
Recommedations 3.00 Quick Ratio 10.42 Shares Outstanding 1B 52W Low Chg 39.00%
Insider Own 1.78% ROA -9.29% Shares Float 0.96B Beta 1.03
Inst Own 8.62% ROE -23.92% Shares Shorted/Prior 43.37M/51.14M Price 0.21
Gross Margin 68.70% Profit Margin -214.70% Avg. Volume 4,078,656 Target Price -
Oper. Margin -147.50% Earnings Date Nov 11 Volume 3,542,397 Change -3.69%
About Zomedica Corp.

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

Zomedica Corp. News
12/19/24 Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer
11/27/24 Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024
11/14/24 Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
11/12/24 Noble Capital Markets Initiates Equity Research Coverage on Zomedica
11/08/24 Zomedica Corp (ZOM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...
11/08/24 Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024
11/07/24 Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth
10/24/24 Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform
06:20 PM Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET
10/15/24 Zomedica Announces Sponsorship of Educational Presentations at the Fetch Coastal Conference
10/09/24 Zomedica Corp (ZOM) Q2 2024 Earnings Call Highlights: Diagnostics Surge Amid Revenue Challenges
10/03/24 Zomedica Announces Expansion of Exclusive Equine Distribution Agreement with Grovet in Europe
09/11/24 Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota
09/05/24 Zomedica Secures CE Mark for TRUVIEWTM Digital Microscope & Telepathology System, Expanding Global Market Opportunities
08/29/24 Zomedica's Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product
08/22/24 Zomedica Introduces Enhanced Audio Features for the VETGuardian(R) Zero-touch Vital Signs Remote Monitoring System
08/20/24 Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference
08/14/24 Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth
08/14/24 Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America
08/01/24 Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET
ZOM Chatroom

User Image Jman236 Posted - 6 minutes from now

$ZOM

User Image CyanHammill Posted - 1 hour ago

$TLRY $ZOM Are you ready? It's time to be first to catch the stock! Our Al Trading Engine, Holly, knows all the secret signs when Big Buyers start Buying!! Christmas sale 25% Off, go:- 𝗮𝗶𝗮𝗹𝗲𝗿𝘁.𝘂𝘀

User Image Givemebreak9891 Posted - 2 hours ago

$ZOM only degenerates dabbles in this stock

User Image odan944 Posted - 4 hours ago

$ZOM

User Image odan944 Posted - 6 hours ago

$ZOM with the new finance specialist hired it is all up from here. With new massive warehouse they have built and going global now… it is all up hill from here. All the hard work they have put into this company will all pay off for everyone including share holders.

User Image Ajlund69 Posted - 12 hours ago

$TNXP $OCGN $ZOM LETS MAKE THIS MONEY

User Image Nubby1 Posted - 1 day ago

$ZOM why has this stock remained under.50 for years without....

User Image GotGreenandGold Posted - 1 day ago

$ZOM

User Image Chris_ZOM Posted - 2 days ago

$ZOM No, I can’t… 😎 https://x.com/naiivememe/status/1870099208637952190?s=46

User Image JP4224 Posted - 2 days ago

$ZOM Let's keep it real, everyone that's been long for 3+ years has banked on Truforma growing exponentially as assays were released, and/or Zomedica continuing to play the company acquisition game for income. So far, new assays haven't moved the needle at all, and we haven't acquired anything new in the last year. Something of substance needs to happen soon, time's ticking

User Image RipVanWinkleman Posted - 2 days ago

$ZOM Just make mouth of Elun Muak say a word, Zomedica. Better tham 10000 staffs' flattering shows and enormous budget spendings.

User Image Meh4ZOM Posted - 2 days ago

@PharmGuy me too. I don't think the expenses are going to be 90 plus mil in 2027,making that year's net loss 27 some million. Previously Jason Kolbert from Dawson James was way too optimistic to the point it was comical and this new analyst seems to be way too pessimistic or overly cautious to the point it is bearish...... My biggest problem with this new report, and this is the only analyst coverage report for ZOM, is that it is painting a bad image for the company's future growth and earning projections in the eye of a potential investor or fund manager......that's what pisses me off. I personally still believe break even should occur EOY 2026 for $ZOM, as long as we remain listed for those 2 years, I am cool with whatever SP.

User Image robteach3 Posted - 2 days ago

$ZOM God damn Larry really scares me. He is not too bright sending out that analyst report that was actually negative for a future outlook.

User Image SugarDtrader Posted - 2 days ago

$ZOM I am definitely going to pull Santa’s beard off. He told me that I was good this year and that Zom will surprise everyone in a favorable way. Unfortunately, he didn’t state when this will happen.

User Image Verified_ Posted - 2 days ago

$zom

User Image Sindel2326 Posted - 2 days ago

$ZOM nice buy at the bell

User Image UPTREND1000 Posted - 2 days ago

$ZOM Shorts, bears and fake bulls are manipulating ZOM all the time. We need capable management to deal with this. ZOM UP UP UP

User Image Kevin89903 Posted - 2 days ago

$ZOM

User Image Chris_ZOM Posted - 2 days ago

$ZOM someone bought 317k shares at the close. 👀

User Image MyChicago Posted - 2 days ago

$ZOM New CFO for Zomedica. https://www.sjordanassociates.com/about-us

User Image Meh4ZOM Posted - 2 days ago

$ZOM the analyst report is actually a bit bearish, it is expecting a net loss of 35.2 mil in 2025 , a net loss of 33.6 mil in 2026, and a net loss of 36.6 m in 2027. While they estimate 58.5 mil total rev in 2027, they are also estimating total expenses to be 95.5 mil in 2027. With these numbers, the 79 mil cash runs out in 2027 Q1. See the table in comments and analyst report. Did any of you actually read this report??? I thought I was being conservative estimating breakeven in EOY 2026 but this analyst doesn't think ZOM will breakeven even at EOY 2027 because of the rapidly growing expenses - I do not really think expenses will be that high tbh. I like to hear what CFO Scott Jordan has to say in March Q4 ER call....

User Image MoneyWizzard Posted - 2 days ago

$ZOM I just bought 11,000 more. It's a good portfolio stocking stuffer.

User Image GuardogJ Posted - 2 days ago

$ZOM manipulation at its finest. SOS.

User Image MoneyWizzard Posted - 2 days ago

$ZOM Maybe Larry will buy some shares back for Christmas.

User Image MyChicago Posted - 2 days ago

$ZOM Nice thought...............Same old shit.

User Image Chris_ZOM Posted - 2 days ago

$ZOM bunch of 100 share sell orders to drive down the momentum. Clowns…

User Image Lambition Posted - 2 days ago

$ZOM Zomedica Pharmaceuticals has appointed Scott A. Jordan as Executive Vice President, Finance and Chief Financial Officer, starting January 1, 2025. With over 30 years of experience in the life sciences and diagnostics industries, Jordan’s strategic finance and business development skills are expected to drive Zomedica’s growth in the animal health sector. His extensive background includes founding S. Jordan Associates and holding key financial roles in biotechnology companies.

User Image wisdon Posted - 2 days ago

$ZOM SNAKE IS A LIVE LFG

User Image Juju_22 Posted - 2 days ago

$zom

User Image Lambition Posted - 2 days ago

$ZOM

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
POWERS JOHNNY D Director Director Nov 17 Buy 0.166 100,000 16,600 1,850,000 11/20/23
POWERS JOHNNY D Director Director May 25 Buy 0.1934 100,000 19,340 1,600,000 05/25/23